During the past decade, Peking University Cancer Hospital conducted 129 clinical trials. In the 10-year time frame, 129 clinical trials started and 5 clinical trials were completed, i.e. on average, 3.9% percent of trials that started reached the finish line to date. In the past 5 years, 66 clinical trials started and 5 clinical trials were completed. i.e. 7.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Peking University Cancer Hospital" #1 sponsor was "Peking University" with 58 trials, followed by "Peking University Cancer Hospital & Institute" with 11 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 5 trials sponsored, "Jiangsu HengRui Medicine Co., Ltd." with 5 trials sponsored and "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" with 5 trials sponsored. Other sponsors include 68 different institutions and companies that sponsored additional 61 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Peking University Cancer Hospital" #1 collaborator was "Peking University Cancer Hospital & Institute" with 14 trials as a collaborator, "Fudan University" with 7 trials as a collaborator, "Hebei Medical University Fourth Hospital" with 6 trials as a collaborator, "Chinese PLA General Hospital" with 5 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 5 trials as a collaborator. Other collaborators include 239 different institutions and companies that were collaborators in the rest 163 trials.

According to Clinical.Site data, the most researched conditions in "Peking University Cancer Hospital" are "Gastric Cancer" (15 trials), "Colorectal Cancer" (9 trials), "Lymphoma" (8 trials), "Breast Cancer" (5 trials) and "Esophageal Squamous Cell Carcinoma" (5 trials). Many other conditions were trialed in "Peking University Cancer Hospital" in a lesser frequency.

Most popular intervention types in "Peking University Cancer Hospital" are "Drug" (98 trials), "Procedure" (19 trials), "Biological" (13 trials), "Device" (13 trials) and "Other" (9 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "18F-FDG PET/CT" (4 trials), "Etoposide" (3 trials), "Irinotecan" (3 trials) and "Laparoscopic gastrectomy" (3 trials). Other intervention names were less common.

The vast majority of trials in "Peking University Cancer Hospital" are 138 trials for "All" genders, 16 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Peking University Cancer Hospital". 7 are not yet recruiting, 48 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Peking University Cancer Hospital, 1 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Peking University Cancer Hospital, 28 "Phase 1" clinical trials were conducted, 51 "Phase 2" clinical trials and 34 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 23 trials that are defined as “Not Applicable".